Rajiv Gandhi Cancer Institute (RGCI), Delhi one of Asia’s premier institutes becomes the first strategic partner to adopt and implement Project Chariot in patients across North India & Delhi NCR region
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Jaypirca is making waves in the fight against B-cell malignancies
The submission is supported by positive results from the Phase 3 AMPLIFY trial
Globally, BRUKINSA is approved in more than 70 countries
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
Comprehensive clinical development programs being initiated for each investigational candidate
Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
Subscribe To Our Newsletter & Stay Updated
